 | • レポートコード：D0-MOR-AP0218 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、細胞株開発の世界市場について調査・分析した資料で、細胞株開発の市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
The global cancer burden is increasing, and thus, cancer therapies must be modified according to regional and national priorities. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world, of which 9.5 million cases were in men and 8.5 million in women. Lung and breast cancers are the most common prevalent cancers, which contributed to about 12.3% of the total number of new cases that were diagnosed in 2018. Colorectal cancer was the third-most common cancer, with a prevalence of 1.8 million new cases in 2018, according to the World Cancer Research Fund. The increasing cancer burden is due to many related factors, including population growth and aging, and the changing prevalence of certain causes of cancer linked to social and economic developments. Cancer is also associated with lifestyles.
The above-mentioned statistics indicate the high burden of cancer across the globe which is expected to drive the growth of cell line development market as there is an increasing demand for the novel therapeutics to deal with cancer.
Key Market Trends
Mammalian Cell Line Development is Expected to Register Rapid Growth Over the Forecast Period
It has been observed that since the year 2006, there has been a rise in the number of recombinant protein therapeutics approved by the FDA. National Institute of Health has stated that there were more than 15 novels recombinant protein therapeutics approved by the US Food and Drug Administration (FDA) each year. In addition, the expiration of the branded drugs has given rise to the emergence of biosimilars. As a result, there is a growing demand for cell line development. Most of the biopharmaceutical companies that develop mammalian cell lines are based on either the methotrexate (MTX) amplification technology or the glutamine synthetase (GS) system.
With the utilization of mammalian cell lines, the cell clones obtained are highly heterogeneous and large numbers of cell clones have to be screened to identify rare stable high producer cell clones. To make the screening process easier, there have been several advances done in the mammalian cell line development which is making it the more preferred source for cell line development. Therefore, with the advancements being done in mammalian cell lines, the segment is expected to witness healthy growth during the future.
United States Dominates the Market
The United States has a better healthcare infrastructure, compared to most of the developed countries. The presence of key players in the United States is the major factor propelling the growth of the market studied in the country. Furthermore, support from the US government to accelerate the research in the biotechnology and biopharmaceutical industry is augmenting the demand for cell line development.
Asia Pacific is expected to witness the highest CAGR over the forecast period due to the growing development in Asian countries such as India, China, and Japan. Also, the Asia Pacific market is posing a great opportunity for new entrants to establish their market in this region.
Competitive Landscape
The cell line development market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as Thermo Fisher Scientific, Sartorius AG, Promega Corporation, and Merck KGaA, is in turn, increasing the overall competitive rivalry in the market. Product advancements and improvement in the cell line development technology by the major players are increasing the competitive rivalry.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Biopharmaceutical Industry
4.2.2 Rising Demand for Monoclonal Antibodies and Cancer Therapeutics
4.2.3 Growing Production of Biosimilars Due to the Patent Expiry of Branded Therapeutics
4.3 Market Restraints
4.3.1 Strict Regulations
4.3.2 Time Taking Process
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Reagent and Media
5.1.2 Equipment
5.1.3 Finished Cells
5.1.4 Other Products
5.2 By Source
5.2.1 Mammalian Cell Line
5.2.2 Non-Mammalian Cell Line
5.3 By Type of Cell Line
5.3.1 Recombinant Cell Lines
5.3.2 Hybridomas Technology
5.3.3 Vaccine Production
5.3.4 Drug Discovery
5.3.5 Other Applications
5.4 By End-User
5.4.1 Biotech Companies
5.4.2 Academics and Research Institutes
5.4.3 Others
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 American Type Culture Collection (ATCC)
6.1.2 Sartorius AG
6.1.3 Danaher Corporation
6.1.4 Merck KGaA
6.1.5 Thermo Fisher Scientific
6.1.6 WuXi Biologics
6.1.7 Corning Incorporated
6.1.8 Selexis SA
6.1.9 Promega Corporation
6.1.10 GE Healthcare
7 MARKET OPPORTUNITIES AND FUTURE TRENDS